Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett; Sandra Belij-Rammerstorfer; Christina Dold; Katie J. Ewer; Pedro M. Folegatti; Ciaran Gilbride; Rachel Halkerston; Jennifer Hill; Daniel Jenkin; Lisa Stockdale; Marije K. Verheul; Parvinder K. Aley; Brian Angus; Duncan Bellamy; Eleanor Berrie; Sagida Bibi; Mustapha Bittaye; Miles W. Carroll; Breeze Cavell; Elizabeth A. Clutterbuck; Nick Edwards; Amy Flaxman; Michelle Fuskova; Andrew Gorringe; Bassam Hallis; Simon Kerridge; Alison M. Lawrie; Aline Linder; Xinxue Liu; Meera Madhavan; Rebecca Makinson; Jack Mellors; Angela Minassian; Maria Moore; Yama Mujadidi; Emma Plested; Ian Poulton; Maheshi N. Ramasamy; Hannah Robinson; Christine S. Rollier; Rinn Song; Matthew D. Snape; Richard Tarrant; Stephen Taylor; Kelly M. Thomas; Merryn Voysey; Marion E.E. Watson; Daniel Wright; Alexander D. Douglas; Catherine M. Green

doi:10.1038/s41591-021-01372-z

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett, Sandra Belij-Rammerstorfer, Christina Dold, Katie J. Ewer, Pedro M. Folegatti, Ciaran Gilbride, Rachel Halkerston, Jennifer Hill, Daniel Jenkin, Lisa Stockdale, Marije K. Verheul, Parvinder K. Aley, Brian Angus, Duncan Bellamy, Eleanor Berrie, Sagida Bibi, Mustapha Bittaye, Miles W. Carroll, Breeze Cavell, Elizabeth A. ClutterbuckNick Edwards, Amy Flaxman, Michelle Fuskova, Andrew Gorringe, Bassam Hallis, Simon Kerridge, Alison M. Lawrie, Aline Linder, Xinxue Liu, Meera Madhavan, Rebecca Makinson, Jack Mellors, Angela Minassian, Maria Moore, Yama Mujadidi, Emma Plested, Ian Poulton, Maheshi N. Ramasamy, Hannah Robinson, Christine S. Rollier, Rinn Song, Matthew D. Snape, Richard Tarrant, Stephen Taylor, Kelly M. Thomas, Merryn Voysey, Marion E.E. Watson, Daniel Wright, Alexander D. Douglas, Catherine M. Green

Research output: Other contribution

9 Citations (Scopus)

Abstract

In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.

Original language	English
Number of pages	1
Edition	6
Volume	27
DOIs	https://doi.org/10.1038/s41591-021-01372-z
Publication status	Published - 1 Jun 2021
Externally published	Yes

Publication series

Name	Nature Medicine
Publisher	Nature Research
ISSN (Print)	1078-8956

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41591-021-01372-z

9 Citations
1 Article

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., Verheul, M. K., Aley, P. K., Angus, B., Bellamy, D., Berrie, E., Bibi, S., Bittaye, M., Carroll, M. W., Cavell, B. & Clutterbuck, E. A. & 30 others, Edwards, N., Flaxman, A., Fuskova, M., Gorringe, A., Hallis, B., Kerridge, S., Lawrie, A. M., Linder, A., Liu, X., Madhavan, M., Makinson, R., Mellors, J., Minassian, A., Moore, M., Mujadidi, Y., Plested, E., Poulton, I., Ramasamy, M. N., Robinson, H., Rollier, C. S., Song, R., Snape, M. D., Tarrant, R., Taylor, S., Thomas, K. M., Voysey, M., Watson, M. E. E., Wright, D., Douglas, A. D. & Green, C. M., 1 Feb 2021, In: Nature Medicine. 27, 2, p. 279-288 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
246 Citations (Scopus)

Cite this

Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., Verheul, M. K., Aley, P. K., Angus, B., Bellamy, D., Berrie, E., Bibi, S., Bittaye, M., Carroll, M. W., Cavell, B., ... Green, C. M. (2021, Jun 1). Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. (6 ed.) https://doi.org/10.1038/s41591-021-01372-z

@misc{5fd79cd7e740434c955f3d0a25facbd4,

title = "Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses",

abstract = "In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection {\textquoteleft}Antibody-dependent neutrophil phagocytosis{\textquoteright} (500,000) and in the fifth sentence of the first paragraph of the Methods subsection {\textquoteleft}Antibody-dependent monocyte phagocytosis{\textquoteright} (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.",

author = "Barrett, \{Jordan R.\} and Sandra Belij-Rammerstorfer and Christina Dold and Ewer, \{Katie J.\} and Folegatti, \{Pedro M.\} and Ciaran Gilbride and Rachel Halkerston and Jennifer Hill and Daniel Jenkin and Lisa Stockdale and Verheul, \{Marije K.\} and Aley, \{Parvinder K.\} and Brian Angus and Duncan Bellamy and Eleanor Berrie and Sagida Bibi and Mustapha Bittaye and Carroll, \{Miles W.\} and Breeze Cavell and Clutterbuck, \{Elizabeth A.\} and Nick Edwards and Amy Flaxman and Michelle Fuskova and Andrew Gorringe and Bassam Hallis and Simon Kerridge and Lawrie, \{Alison M.\} and Aline Linder and Xinxue Liu and Meera Madhavan and Rebecca Makinson and Jack Mellors and Angela Minassian and Maria Moore and Yama Mujadidi and Emma Plested and Ian Poulton and Ramasamy, \{Maheshi N.\} and Hannah Robinson and Rollier, \{Christine S.\} and Rinn Song and Snape, \{Matthew D.\} and Richard Tarrant and Stephen Taylor and Thomas, \{Kelly M.\} and Merryn Voysey and Watson, \{Marion E.E.\} and Daniel Wright and Douglas, \{Alexander D.\} and Green, \{Catherine M.\}",

year = "2021",

month = jun,

day = "1",

doi = "10.1038/s41591-021-01372-z",

language = "English",

volume = "27",

series = "Nature Medicine",

publisher = "Nature Research",

edition = "6",

type = "Other",

}

Barrett, JR, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD & Green, CM 2021, Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. https://doi.org/10.1038/s41591-021-01372-z

TY - GEN

T1 - Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

AU - Barrett, Jordan R.

AU - Belij-Rammerstorfer, Sandra

AU - Dold, Christina

AU - Ewer, Katie J.

AU - Folegatti, Pedro M.

AU - Gilbride, Ciaran

AU - Halkerston, Rachel

AU - Hill, Jennifer

AU - Jenkin, Daniel

AU - Stockdale, Lisa

AU - Verheul, Marije K.

AU - Aley, Parvinder K.

AU - Angus, Brian

AU - Bellamy, Duncan

AU - Berrie, Eleanor

AU - Bibi, Sagida

AU - Bittaye, Mustapha

AU - Carroll, Miles W.

AU - Cavell, Breeze

AU - Clutterbuck, Elizabeth A.

AU - Edwards, Nick

AU - Flaxman, Amy

AU - Fuskova, Michelle

AU - Gorringe, Andrew

AU - Hallis, Bassam

AU - Kerridge, Simon

AU - Lawrie, Alison M.

AU - Linder, Aline

AU - Liu, Xinxue

AU - Madhavan, Meera

AU - Makinson, Rebecca

AU - Mellors, Jack

AU - Minassian, Angela

AU - Moore, Maria

AU - Mujadidi, Yama

AU - Plested, Emma

AU - Poulton, Ian

AU - Ramasamy, Maheshi N.

AU - Robinson, Hannah

AU - Rollier, Christine S.

AU - Song, Rinn

AU - Snape, Matthew D.

AU - Tarrant, Richard

AU - Taylor, Stephen

AU - Thomas, Kelly M.

AU - Voysey, Merryn

AU - Watson, Marion E.E.

AU - Wright, Daniel

AU - Douglas, Alexander D.

AU - Green, Catherine M.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.

AB - In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article. *A full list of authors and their affiliations appears at the end of the paper.

U2 - 10.1038/s41591-021-01372-z

DO - 10.1038/s41591-021-01372-z

M3 - Other contribution

VL - 27

T3 - Nature Medicine

ER -

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Abstract

Publication series

UN SDGs

Access to Document

Fingerprint

Research output

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Cite this